Harpoon Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage biotechnology company headquartered in South San Francisco, California, and founded in 2015, develops novel T-cell engagers using its proprietary Tri-specific T cell Activating Construct (TriTAC) platform, ProTriTAC prodrug platform, and TriTAC-XR extended-release platform to treat solid tumors and hematologic malignancies including small cell lung cancer, neuroendocrine tumors, multiple myeloma, ovarian cancer, pancreatic cancer, and prostate cancer; core product candidates include HPN328 (now MK-6070), a DLL3-targeting TriTAC in Phase 1/2 trials for DLL3-expressing advanced cancers, HPN217, a BCMA-targeting TriTAC in Phase 1 trials for relapsed/refractory multiple myeloma, HPN536 targeting mesothelin for ovarian and pancreatic cancers, HPN424 targeting PSMA for prostate cancer, and preclinical HPN601 targeting EpCAM. The company operates primarily in the United States with a focus on oncology immunotherapy for patients with high unmet needs in target markets worldwide. In March 2024, Merck & Co., Inc. (NYSE: MRK), through a subsidiary, completed its acquisition of Harpoon for approximately $680 million at $23.00 per share in cash, making Harpoon a wholly-owned subsidiary integrated into Merck's oncology pipeline, with HPN328 advancing in combination studies such as with atezolizumab and recording a $650 million non-tax deductible R&D charge for Merck.
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
Merck to Buy Harpoon Therapeutics for $680 Million
Merck to buy Harpoon Therapeutics for $680 million
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Merck close to acquiring cancer specialist Harpoon Therapeutics
Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News
Harpoon Therapeutics Strengthens Leadership Team
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross?
Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stock to Buy for December 5th
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade